Spectromicroscopy of boron in human glioblastomas following administration of Na2B12H11SH.
Boron neutron capture therapy (BNCT) is an experimental, binary treatment for brain cancer which requires as the first step that tumor tissue is targeted with a boron-10 containing compound. Subsequent exposure to a thermal neutron flux results in destructive, short range nuclear reaction within 10 microm of the boron compound. The success of the therapy requires than the BNCT agents be well localized in tumor, rather than healthy tissue. The MEPHISTO spectromicroscope, which performs microchemical analysis by x-ray absorption near edge structure (XANES) spectroscopy from microscopic areas, has been used to study the distribution of trace quantities of boron in human brain cancer tissues surgically removed from patients first administered with the compound Na2B12H11SH (BSH). The interpretation of XANES spectra is complicated by interference from physiologically present sulfur and phosphorus, which contribute structure in the same energy range as boron. We addressed this problem with the present extensive set of spectra from S, B, and P in relevant compounds. We demonstrate that a linear combination of sulfate, phosphate and BSH XANES can be used to reproduce the spectra acquired on boron-treated human brain tumor tissues. We analyzed human glioblastoma tissue from two patients administered and one not administered with BSH. As well as weak signals attributed to BSH, x-ray absorption spectra acquired from tissue samples detected boron in a reduced chemical state with respect to boron in BSH. This chemical state was characterized by a sharp absorption peak at 188.3 eV. Complementary studies on BSH reference samples were not able to reproduce this chemical state of boron, indicating that it is not an artifact produced during sample preparation or x-ray exposure. These data demonstrate that the chemical state of BSH may be altered by in vivo metabolism.
Gilbert
B
B
Institut de Physique Appliquée, Ecole Polytechnique Fédérale, PH-Ecublens, CH-1015 Lausanne, Switzerland.
Perfetti
L
L
Fauchoux
O
O
Redondo
J
J
Baudat
P A
PA
Andres
R
R
Neumann
M
M
Steen
S
S
Gabel
D
D
Mercanti
D
D
Ciotti
M T
MT
Perfetti
P
P
Margaritondo
G
G
De Stasio
G
G
D001894:Borohydrides / Q000032:analysis / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D001895:Boron / Q000032:analysis* / Q000737:chemistry / Q000378:metabolism; D001896:Boron Compounds / Q000032:analysis; D016754:Boron Neutron Capture Therapy; D001932:Brain Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000532:radiotherapy*; D005909:Glioblastoma / Q000188:drug therapy / Q000378:metabolism / Q000532:radiotherapy*; D006801:Humans; D008867:Microtomy; D013057:Spectrum Analysis; D013438:Sulfhydryl Compounds / Q000032:analysis / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D013455:Sulfur; D014965:X-Rays
D001894:Borohydrides; D001896:Boron Compounds; D013438:Sulfhydryl Compounds; C014651:mercaptoundecahydrododecaborate; C042168:boron oxide; D013455:Sulfur; D001895:Boron